Condition
Hyperglucagonemia
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 1 (1)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05056584Not ApplicableCompleted
The Role of the Kidneys and Liver in the Elimination of Glucagon
NCT02237053Phase 1CompletedPrimary
Effects of Glucagon Administration on Energy Expenditure
NCT01436734Not ApplicableCompletedPrimary
Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125
NCT00862589Not ApplicableCompleted
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00704795UnknownPrimary
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
Showing all 5 trials